Publication at Faculty of Medicine in Pilsen |
2020
Abstract
The treatment of multiple sclerosis has undergone significant progress in recent decades. New modern drugs bring a high ability to suppress the activity of this disease and protect the patient from future disability.
From this point of view, emphasis is placed not only on their sufficient effectiveness, but also on long-term safety, therefore the long-term efficacy and safety data of all new drugs are monitored. This article focuses specifically on ocrelizumab data.
A drug that is used today to treat not only the relapsing-remitting form of MS, but also as the first drug in history to treat primarily progressive MS.